BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17609951)

  • 1. Activation and route of administration both determine the ability of bone marrow-derived dendritic cells to accumulate in secondary lymphoid organs and prime CD8+ T cells against tumors.
    Huck SP; Tang SC; Andrew KA; Yang J; Harper JL; Ronchese F
    Cancer Immunol Immunother; 2008 Jan; 57(1):63-71. PubMed ID: 17609951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine.
    Lutz-Nicoladoni C; Wallner S; Stoitzner P; Pircher M; Gruber T; Wolf AM; Gastl G; Penninger JM; Baier G; Wolf D
    Immunol Cell Biol; 2012 Jan; 90(1):130-4. PubMed ID: 21383769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conventional dendritic cells are required for the activation of helper-dependent CD8 T cell responses to a model antigen after cutaneous vaccination with lentiviral vectors.
    Goold HD; Escors D; Conlan TJ; Chakraverty R; Bennett CL
    J Immunol; 2011 Apr; 186(8):4565-72. PubMed ID: 21389256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin C treatment of mouse bone marrow-derived dendritic cells enhanced CD8(+) memory T cell production capacity of these cells in vivo.
    Jeong YJ; Kim JH; Hong JM; Kang JS; Kim HR; Lee WJ; Hwang YI
    Immunobiology; 2014 Jul; 219(7):554-64. PubMed ID: 24698552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L mAb.
    Lu L; Li W; Zhong C; Qian S; Fung JJ; Thomson AW; Starzl TE
    Transplantation; 1999 Sep; 68(6):747-57. PubMed ID: 10515374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity.
    Hermans IF; Ritchie DS; Yang J; Roberts JM; Ronchese F
    J Immunol; 2000 Mar; 164(6):3095-101. PubMed ID: 10706699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
    Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
    J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen presentation by an immature myeloid dendritic cell line does not cause CTL deletion in vivo, but generates CD8+ central memory-like T cells that can be rescued for full effector function.
    Dumortier H; van Mierlo GJ; Egan D; van Ewijk W; Toes RE; Offringa R; Melief CJ
    J Immunol; 2005 Jul; 175(2):855-63. PubMed ID: 16002683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors.
    Gabrilovich DI; Nadaf S; Corak J; Berzofsky JA; Carbone DP
    Cell Immunol; 1996 May; 170(1):111-9. PubMed ID: 8665591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
    Sun JB; Eriksson K; Li BL; Lindblad M; Azem J; Holmgren J
    Clin Immunol; 2004 Jul; 112(1):35-44. PubMed ID: 15207780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of mouse dendritic cell migration in vivo upon subcutaneous and intravenous injection.
    Lappin MB; Weiss JM; Delattre V; Mai B; Dittmar H; Maier C; Manke K; Grabbe S; Martin S; Simon JC
    Immunology; 1999 Oct; 98(2):181-8. PubMed ID: 10540216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.
    Paglia P; Chiodoni C; Rodolfo M; Colombo MP
    J Exp Med; 1996 Jan; 183(1):317-22. PubMed ID: 8551239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.
    Kim MT; Richer MJ; Gross BP; Norian LA; Badovinac VP; Harty JT
    J Immunol; 2015 Nov; 195(9):4537-44. PubMed ID: 26408669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic and functional characterization of mouse hepatic CD8 alpha+ lymphoid-related dendritic cells.
    O'Connell PJ; Morelli AE; Logar AJ; Thomson AW
    J Immunol; 2000 Jul; 165(2):795-803. PubMed ID: 10878353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The duration of signaling through CD40 directs biological ability of dendritic cells to induce antitumor immunity.
    Watanabe S; Kagamu H; Yoshizawa H; Fujita N; Tanaka H; Tanaka J; Gejyo F
    J Immunol; 2003 Dec; 171(11):5828-36. PubMed ID: 14634092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.
    Prins RM; Craft N; Bruhn KW; Khan-Farooqi H; Koya RC; Stripecke R; Miller JF; Liau LM
    J Immunol; 2006 Jan; 176(1):157-64. PubMed ID: 16365406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Both dendritic cells and macrophages can stimulate naive CD8 T cells in vivo to proliferate, develop effector function, and differentiate into memory cells.
    Pozzi LA; Maciaszek JW; Rock KL
    J Immunol; 2005 Aug; 175(4):2071-81. PubMed ID: 16081773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
    Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
    Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.